Your browser doesn't support javascript.
loading
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.
Bagheri-Yarmand, Rozita; Busaidy, Naifa L; McBeath, Elena; Danysh, Brian P; Evans, Kurt W; Moss, Tyler J; Akcakanat, Argun; Ng, Patrick K S; Knippler, Christina M; Golden, Jalyn A; Williams, Michelle D; Multani, Asha S; Cabanillas, Maria E; Shaw, Kenna R; Meric-Bernstam, Funda; Shah, Manisha H; Ringel, Matthew D; Hofmann, Marie Claude.
Afiliação
  • Bagheri-Yarmand R; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Busaidy NL; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • McBeath E; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Danysh BP; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Evans KW; Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Moss TJ; Bioinformatics & Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Akcakanat A; Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Ng PKS; Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Knippler CM; Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
  • Golden JA; Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA 30322, USA.
  • Williams MD; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Multani AS; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Cabanillas ME; Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Shaw KR; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Meric-Bernstam F; Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Shah MH; Department of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Ringel MD; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
  • Hofmann MC; Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Cancers (Basel) ; 13(19)2021 Sep 30.
Article em En | MEDLINE | ID: mdl-34638434
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos